Therapeuticsmd, inc. (TXMD)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Product revenue, net

12,250

15,901

23,719

6,078

3,946

5,089

3,473

3,763

3,773

4,124

4,417

4,250

3,985

4,487

5,535

4,403

4,930

5,629

5,190

4,847

4,475

4,257

4,186

3,751

2,830

2,862

2,294

2,080

1,537

1,240

1,036

819

721

554

539

508

485

-

-

Cost of goods sold

2,715

2,878

1,444

1,248

762

950

699

454

633

594

700

681

659

709

1,237

1,130

1,108

1,235

1,193

1,033

1,043

879

1,068

892

830

467

648

463

380

332

306

372

336

262

241

238

203

-

-

Gross profit

9,535

13,023

22,275

4,830

3,183

4,138

2,774

3,308

3,139

3,529

3,716

3,568

3,325

3,777

4,298

3,273

3,821

4,393

3,996

3,814

3,431

3,378

3,117

2,858

1,999

2,395

1,646

1,617

1,156

907

729

446

385

291

297

269

282

-

-

Operating expenses:
Sales, general, and administrative

56,927

52,734

45,126

41,387

34,864

35,410

30,354

29,466

20,757

14,178

12,057

14,628

16,837

16,329

14,721

10,619

9,678

8,631

7,060

6,865

6,163

5,514

6,043

5,537

5,029

4,259

4,752

5,476

4,526

4,745

2,923

3,573

2,827

2,587

1,633

1,200

985

-

-

Research and development

3,268

4,432

4,077

4,964

6,317

6,753

6,708

6,798

7,039

10,974

6,436

8,716

7,724

10,341

14,664

13,841

15,097

13,253

16,421

24,190

18,176

14,166

14,909

8,234

5,908

6,140

4,098

1,747

1,565

1,544

1,702

833

411

-148

95

106

54

-

-

Depreciation and amortization

261

248

141

115

106

95

73

65

59

56

54

53

49

48

40

24

19

18

16

14

13

12

12

14

13

7

32

10

7

12

14

14

14

13

13

13

13

-

0

Operating revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Operating costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

General and administration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

66

66

Total operating expenses

60,457

57,415

49,346

46,466

41,288

42,259

37,135

36,330

27,856

25,210

18,548

23,398

24,612

26,718

29,426

24,484

24,795

21,902

23,499

31,070

24,354

19,693

20,965

13,785

10,950

10,406

8,883

7,234

6,099

6,303

4,640

4,421

3,253

2,452

1,742

1,320

1,053

66

66

Operating loss

-50,922

-44,392

-27,071

-41,636

-38,105

-38,120

-34,361

-33,021

-24,716

-21,680

-14,831

-19,829

-21,286

-22,940

-25,128

-21,211

-20,973

-17,508

-19,503

-27,255

-20,922

-16,315

-17,847

-10,927

-8,950

-8,011

-7,237

-5,616

-4,942

-5,395

-3,910

-3,974

-2,868

-2,160

-1,444

-1,050

-771

-

-

Other income (expense)
Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

260

395

447

395

263

0

0

0

0

-

-

-

-

-

-

Loan guaranty costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2

9

11

11

11

11

11

11

2

-

-

Loss on extinguishment of debt

-

-

-

-10,057

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

197

-197

0

-10,307

-7,390

0

0

0

-

-

Miscellaneous income

335

621

703

486

688

823

809

334

314

253

167

149

125

101

109

114

41

32

27

25

9

3

6

18

18

19

11

3

0

-

0

1

-

-

0

0

-

-

0

Beneficial conversion feature

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-6,716

-

-

0

0

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

3

-

-

-

Interest expense

6,262

5,664

5,599

4,028

2,090

-

2,053

531

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,165

520

134

1,148

101

47

16

0

0

55

8

Accreted interest

-

-

-

-

-

-

-

-

-

0

0

3

3

2

2

2

2

-6

2

2

18

9

9

9

9

-

0

-

0

-

0

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Total other expense

-5,926

-5,043

-4,895

-13,599

-1,401

-1,270

-1,244

-197

314

253

167

152

129

104

112

117

44

26

30

28

28

12

15

27

-232

-349

-436

-392

-1,432

-332

-342

-7,875

-10,421

-7,425

-42

-15

-2

-55

-8

Loss before income taxes

-56,848

-49,435

-31,966

-55,236

-39,506

-39,390

-35,605

-33,219

-24,401

-21,427

-14,664

-19,676

-21,156

-22,836

-25,015

-21,094

-20,929

-17,482

-19,472

-27,227

-20,894

-16,302

-17,832

-10,899

-9,183

-8,361

-7,673

-6,009

-6,375

-5,727

-4,253

-11,850

-13,289

-9,585

-1,486

-1,066

-774

-122

-75

Provision for income taxes

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

0

-

-

0

-

-

-

-

0

-

-

-

-

0

0

0

0

-

0

0

0

0

0

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-122

-75

Gain on disposal of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

259

0

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-107

-193

Income (loss) from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

152

-193

Net loss

-56,848

-49,435

-31,966

-55,236

-39,506

-39,390

-35,605

-33,219

-24,401

-21,427

-14,664

-19,676

-21,156

-22,836

-25,015

-21,094

-20,929

-17,482

-19,472

-27,227

-20,894

-16,302

-17,832

-10,899

-9,183

-8,361

-7,673

-6,009

-6,375

-5,727

-4,253

-11,850

-13,289

-9,585

-1,486

-1,066

-774

29

-269

Loss per share, basic and diluted:
From continuing operations, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

0.00

From discontinued operations, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

-0.01

Net loss per share, basic and diluted

-0.21

-0.20

-0.13

-0.23

-0.16

-0.17

-0.16

-0.15

-0.11

-0.09

-0.07

-0.10

-0.11

-0.11

-0.13

-0.11

-0.11

-0.09

-0.11

-0.16

-0.13

-0.11

-0.12

-0.07

-0.06

-0.05

-0.06

-0.05

-0.06

-0.04

-0.04

-0.14

-0.16

-0.15

-0.03

-0.02

-0.01

0.00

-0.02

Weighted average number of common shares outstanding, basic and diluted

271,459

261,924

241,261

241,221

241,006

238,832

228,107

216,640

216,525

212,980

207,938

203,384

197,790

196,623

196,502

196,325

194,901

179,260

177,206

172,782

163,448

156,203

152,200

145,485

145,019

145,161

131,212

130,851

103,052

99,921

95,895

86,149

84,556

78,492

58,407

57,455

55,710

15,790

15,894

Product [Member]
Total revenue, net

-

-

8,213

-

-

-

3,473

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License and Service [Member]
Total revenue, net

-

-

15,506

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-